HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Alveolitis of jaw — Clinical Guidelines

Overview

Osteonecrosis of the jaw (ONJ) is a severe, often debilitating condition characterized by exposed bone in the maxillofacial region lasting more than eight weeks, frequently associated with the use of certain medications including bisphosphonates, monoclonal antibodies, and small-molecule inhibitors 1 3 5.

Diagnosis

Clinical Presentation: Exposed bone in the maxillofacial region persisting for more than eight weeks 1 3.

Risk Factors: History of bisphosphonate use, particularly intravenous forms; concurrent use of antiangiogenic agents, RANKL inhibitors, and other specified medications 1 3 5.

Diagnostic Tests: Radiographic imaging (X-rays, CT scans) to confirm bone exposure and assess extent 1 3.

Grading Systems: No universally standardized grading system suitable for spontaneous reporting databases; AAOMS criteria often not fully applicable 4.

Management

Drug Cessation: Discontinue offending agents if possible 1 8.

Local Care: Maintain oral hygiene, surgical debridement if necessary 8.

Supportive Measures: Nutritional support, pain management, infection control 8.

Monitoring: Regular follow-up with imaging to monitor healing 8.

Special Populations

Elderly: Higher risk due to prolonged medication use and comorbid conditions 3 5.

Cancer Patients: Increased risk, especially with zoledronate and denosumab use for skeletal-related events prevention 3.

Key Recommendations

Avoid Concurrent Risk Factors: Minimize concurrent use of chemotherapy and other risk factors for ONJ in patients on bisphosphonates (Evidence: Moderate 6).

Regular Monitoring: Implement regular dental and radiographic monitoring in high-risk patients on long-term bisphosphonate therapy (Evidence: Moderate 3 5).

Prompt Intervention: Early recognition and intervention, including cessation of causative medications and appropriate local care, are crucial (Evidence: Expert opinion 8).

References

1 Sridharan K, Sivaramakrishnan G. Monoclonal Antibodies and Small-Molecule Inhibitors Associated Osteonecrosis of Jaw: A Retrospective Pharmacovigilance Study. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2025. link 2 Neha R, Beulah E, Anusha B, Vasista S, Stephy C, Subeesh V. Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals. International journal of clinical pharmacy 2020. link 3 Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY et al.. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2016. link 4 de Boissieu P, Trenque T. Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jaw. Expert opinion on drug safety 2015. link 5 Parretta E, Sottosanti L, Sportiello L, Rafaniello C, Potenza S, D'Amato S et al.. Bisphosphonate-related osteonecrosis of the jaw: an Italian post-marketing surveillance analysis. Expert opinion on drug safety 2014. link 6 de Boissieu P, Kanagaratnam L, Abou Taam M, Roux MP, Dramé M, Trenque T. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiology and drug safety 2014. link 7 Kharazmi M, Persson U, Warfvinge G. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2012. link 8 Capsoni F, Longhi M, Weinstein R. Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role. Arthritis research & therapy 2006. link 9 Sosis M, Lazar S. Jaw dislocation during general anaesthesia. Canadian journal of anaesthesia = Journal canadien d'anesthesie 1987. link

Alveolitis of jaw